USMCA Trade Deal Will Keep U.S. Drug Prices High, Groups Warn

International Pharmaceutical Regulatory Monitor
The Trump administration’s newly negotiated trade deal with Canada and Mexico threatens to keep American drug prices high, two dozen-plus consumer, health, trade and other organizations warned in a letter to the U.S. Trade Representative. The 29 groups — including the Association for Accessible Medicines (AAM) and the AARP — claim some provisions in the proposed NAFTA overhaul are inconsistent with U.S. law.

To View This Article:


Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00